Attovia Therapeutics Inc.
ATTO | NASDAQ
$21.30
-$0.84 (-3.79%)
At close: Sep 21, 2026, 4:00 PM ET
Fiscal Year Period Ending | FY 2025 Dec 30, 2025 | FY 2024 Dec 30, 2024 |
|---|---|---|
Revenue | 1.35M | n/a |
Cost of Revenue | 804K | 313K |
Gross Profit | 546K | -313K |
Operating Income | -67.16M | -41.55M |
Interest Income | 6.63M | 3.44M |
Pretax Income | -60.63M | -39.8M |
Net Income | -60.63M | -39.8M |
Selling & General & Admin | 13.55M | 7.38M |
Research & Development | 54.15M | 33.86M |
Other Expenses | n/a | n/a |
Operating Expenses | 67.71M | 41.24M |
Interest Expense | n/a | n/a |
Selling & Marketing Expenses | n/a | n/a |
Cost & Expenses | 68.51M | 41.55M |
Income Tax Expense | n/a | n/a |
Shares Outstanding (Basic) | 43.03M | 43.03M |
Shares Outstanding (Diluted) | 43.03M | 43.03M |
EPS (Basic) | -1.42 | -1.05 |
EPS (Diluted) | -1.42 | -1.05 |
EBITDA | -66.36M | -41.24M |
EBIT | -67.16M | -41.55M |
Depreciation & Amortization | 804K | 313K |
Add to Watchlist
Select watchlists to add or remove ATTO